Teclistamab for previously treated relapsed or refractory multiple myeloma

Teclistamab is in clinical development for the treatment of relapsed or refractory multiple myeloma (MM) in patients who have received at least three prior lines of therapy. MM is a rare, incurable blood cancer that forms in the plasma calls in the bone marrow, inside some of the large bones of the body. The cancerous cells build up and interfere with production of red and white blood cells, and platelets. MM is an incurable disease so patients go through periods of being symptom-free following treatment before the illness returns/ relapses and can no longer be treated with the same therapies (becomes resistant/ refractory). Patients often go through the cycle many times and new treatment options could increase the lengths overall survival.